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Giant cell tumor of bone (GCTB) is a rare condition with distinct radiological features that
aid diagnosis. We present the case of an adult female patient, with locally invasive GCTB
and review important radiological and management principles. Specific radiological fea-
tures include locally aggressive, lytic radiolucent lesions, which can demonstrate cortical
thinning and expansile remodeling of bone and typically involve the epiphysis and met-
aphysis. Management is primarily surgical, and denosumab has a role in the advanced
setting.
© 2016 the Authors. Published by Elsevier Inc. under copyright license from the University
of Washington. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Case
We present the case of a 31-year-old Polish lady who pre-
sented to the Emergency Department with a 10-month history
of progressively worsening thoracic pain. This pain radiated
laterally, and she had associated parathesia. On examination,
she was in significant distress due to pain. She was afebrile,
her pulse was 93 bpm; oxygen saturation on room air 99%;
respiratory rate 16; blood pressure 122/85. Full clinical exam-
ination did not reveal a cause for her symptoms. Her labora-
tory investigations were normal. She had no significant
personal or family medical history. A thoracic x-ray demon-
strated a radiolucent T8 vertebral body. (Fig. 1)lared that no competing i
.com (D. Kelly).
Elsevier Inc. under copy
se (http://creativecommoA noncontrast computed tomography (CT) thoracic spine
demonstrated an expansile soft tissue mass within the T8
vertebral body extending into the pedicles bilaterally. There
was associated cortical destruction, and the mass abutted the
right posterior pleura and extended into the right anterior
spinal canal. Therewas a lack ofmatrixmineralization (Fig. 2).
Magnetic resonance imaging spine demonstrated diffusely
abnormal marrow signal within the T8 vertebral body with a
solid and cystic mass lesion extending into the pedicles
bilaterally; worse on the left. The solid component displayed
mild postcontrast enhancement. The spine at other levels
was normal, and there was no evidence of metastatic disease
(Figs. 3-5). Possible differentials included a plasmacytoma,nterests exist.
right license from the University of Washington. This is an open
ns.org/licenses/by-nc-nd/4.0/).
Fig. 1 e AP radiograph of thoracic spine. The arrow
demonstrates subtle increased lucency of the T8 vertebral
body with mild loss of vertebral body height. No evidence
of sclerosis. Fig. 3 e T1-weighted magnetic resonance imaging spine
(sagittal). Diffusely abnormal marrow signal within the T8
vertebral body with complete replacement of the vertebral
body by tumor demonstrating T1 hypointense signal.
Bowing of the posterior cortex into the spinal canal.
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tumor, chordoma, chondroblastoma or lymphoma.
She had a CT guided core biopsy of T8. Histology from this
sample revealed a giant cell tumor of bone (GCTB) with sur-
rounding reactive and regenerative changes of surrounding
bone (Fig. 6). Numerous multinucleated giant cells were pre-
sent but no necrosis and only occasionalmitoses. This process
infiltrated the bone, but there was no atypia present (Fig. 2).
Radiological features were consistent with a grade 3 lesion as
per the Campanacci grading system for GCTB [1].Fig. 2 e Noncontrast computed tomography (CT) thoracic
spine. Expansile soft tissue mass within the T8 vertebral
body extending into the pedicles bilaterally. There is
extraosseous extension at sites of cortical destruction,
abutting the right posterior pleura (arrowhead), and
extending into the right anterior spinal canal (long arrow).
Note lack of internal bone matrix within the lesion.The patient underwent an anterior T8 corpectomy, spinal
decompression, and fusion without complication. Subse-
quently, she proceeded to a posterior stabilization of T8 (Fig. 7).
Final histology demonstrated a well-circumscribed GCTBwith
negative margins. The case was reviewed at the Oncology
Multidisciplinary Team Meeting. The decision was made to
proceed with active surveillance and not for adjuvant therapy
because of the limited evidence for benefit. The patient is
currently doing well 18 months from her initial diagnosis.Discussion
GCTB is a rare, locally aggressive tumor, which accounts for
5% of primary bone tumors. It rarely manifests in an imma-
ture skeleton and usually occurs in patients with closed
physes [4e6] between the ages of 20-40 years; typically
effecting females slightly more frequently than males [1].
GCBTs typically occur within the epiphysiometaphyseal re-
gion of long bones and are eccentric in location [5,16e20].
Lesions, typically demonstrate geographic bone lysis, are
usually associated with a narrow zone of transition, abut the
articular margin, and lack a surrounding sclerotic rim [4].
Involvement of the vertebra is uncommon, and the most
common sites of GCBT are around the knee: distal femur and
proximal tibia (50%-65%) followed by the distal radius (10%-
12%) and sacrum (4%-9%) [1]. Metastases are rare occurring in
1% of cases [2,3].
X-ray and CT imaging can demonstrate well the locally
aggressive processes associated with GCBT. Plain radiographs
typically demonstrate a radiolucent lesion with a sharply
defined, nonsclerotic border [21]. There is no periosteal
response [4e6], unless fractured. Pathologic fractures are
Fig. 4 e T2-weighted magnetic resonance imaging spine
(sagittal). There is a hypointense mass within the T8
vertebral body with some cystic T2 hyperintense
components posteriorly and extension into the posterior
spinal canal.
Fig. 6 e Histology giant cell tumor of bone. Histology shows
surrounding reactive and regenerative changes, numerous
multinucleated giant cells, no necrosis, occasional mitoses,
infiltrating the bone and no atypia.
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features such as cortical thinning, expansile remodeling, and
a wide transition zone (Fig. 3) [5,16e19]. GCBTs typically
demonstrate prominent trabeculation and a loculated
appearance [4]; however, this has been thought to actually
represent pseudotrabeculation because of prominent osseous
ridges caused by endosteal scalloping [22]. CT is superior to
plain radiography in the detection of cortical thinning, path-
ologic fractures, periosteal reaction, the degree of osseousFig. 5 e Magnetic resonance imaging axial spineeT1 fat-
saturated postcontrast. Mild peripheral enhancement post
IV contrast.expansile remodeling, and lack of matrix mineralization
[23,24].
Magnetic resonance imaging is helpful in demonstrating
whether there is extension through the articular surface, as
well as marrow and soft tissue changes (Figs. 4 and 5). The
solid component of giant cell bone tumors typically demon-
strates intermediate signal intensity on T1-weighted images
and hypointense signal on T2-weighted images because of the
presence of collagen within fibrous components and because
of hemosiderin deposition within the tumor [21]. Imaging post
IV gadolinium administration can help differentiate between
solid and cystic portions of the tumor and can aid image-
guided targetted biopsy of the solid component of the lesion
[21]. Fluid-fluid levels may be identified within the tumor and
can be due to the presence of an aneurysmal bone cyst or due
to intralesional hemorrhage [25,26]. GCBT is the most com-
mon lesion to be associated with secondary aneurysmal bone
cysts, present in 19%-39% of cases [4,5,17,27], and it has been
reported that the presence of secondary aneurysmal bone
cysts are associated with an increased risk of local tumor
recurrence [27,28].
The differential diagnosis for a possible case of spinal GCBT
includes a metastasis, plasmacytoma, chordoma, chondro-
blastoma, or sarcoma (eg telangiectatic osteosarcoma)
[5,16,17].
Surgery is the preferred treatment for GCTB, with lower
recurrence rates after en bloc resection. The options for
surgery include intralesional currettage, marginal excision,
wide local excision, or en bloc resection. It depends where
and how extensive the tumor is. En bloc resection is
considered where there is extensive cortex destruction (as in
this case) or if it is impossible to salvage the joint [7,8]. The
rate of recurrence is 10%-20% and will often occur locally.
Other options for local control include curettage and appli-
cation of intralesional heat, freezing or ablative agents, for
example, phenols [3].
GCTB contain stromal cells, monocytes, and osteoclast-like
giant cells [9]. The osteoclasts cause the damaging osteolysis
that results in the morbidity associated with GCTB [9]. Oste-
oclast differentiation and recruitment depends on several
factors; including receptor activator of nuclear factor kappa B
Fig. 7 e AP radiograph thoracic spine post operatively. AP
radiograph demonstrating appearances post T8
corpectomy with graft interposition and bilateral
longitudinal rods fixated using transpedicular screws. L,
patient's left side.
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cells in the GCTB, resulting in osteoclast recruitment and
activation [9,10]. Therefore, this and the other molecules that
mediate this process can be targeted with molecular therapy.
Denosumab is a human monoclonal antibody that specif-
ically inhibits RANKL, and therefore inhibits osteoclast-driven
bone destruction [2]. An important phase II study by Thomas
et al showed 30 of 35 patients with recurrent or surgically
unresectable disease demonstrated a tumor response when
given denosumab [1]. This confirms that targeting RANKL
signaling is a valuable strategy in treating GCTB.
Following on from this, Chawla et al carried out another
Phase II trial to evaluate the safety and efficacy of denosumab
[11]. The authors found that denosumab had an acceptable
safety profile and was an effective treatment for GCTB. Their
results showed that treatment with denosumab could reduce
the morbidity of planned surgery or eliminate the need for
surgery [11]. Median follow-up was 1 year, so further long-
term data is required.Owing to the low rate of associated adverse effects and
demonstrated high rate of tumor control, denosumab has
been approved by the European Medicines Agency as treat-
ment for patients with unresectable GCTB or when surgical
resection is likely to result in severe morbidity.
There is weak evidence that bisphosphonate use in GCTB
may improve symptoms and local disease control [12]. A
caseecontrol study by Tse et al [13] demonstrated a reduced
rate of tumor recurrence after using bisphosphonates as
adjuvant therapy to intralesional curettage or excision. How-
ever, bisphosphonate use in the adjuvant setting has not been
approved, and the role of these drugs is not clear.
Interferon (IFN) or pegylated interferon is included as a
treatment option in the NCCN guidelines for GCTB that are
unresectable or metastatic at presentation. GCTB has been
found to have overexpression of angiogenic growth factors,
and so IFN is used to target this. The evidence for its efficacy is
anecdotal. Given that IFN is poorly tolerated, other treatment
options may be preferable in this setting [14,15].
In conclusion, although GCTB is rare, there are distinct
radiological features associated, which can aid diagnosis. Se-
vere morbidity can occur due to its locally destructive effects.
Management is primarily surgical. Denosumab has demon-
strated tumor control in unresectable disease; however, its
efficacy in the adjuvant setting is under investigation at
present.Learning points
 GCTerarely occur within the vertebrae above the sacrum.
 Imaging (CT) useful to target biopsy to the solid portion.
 Surgery can be curative.
 Key points inmaking radiological diagnosis of GCT of bone:
- occur in patients with closed physes within epi-
physiometaphyseal region of long bones;
- narrow zone of transition;
- abut the articular surface;
- eccentric in location;
- lack sclerotic rim;
- may be associated with a secondary aneurysmal bone
cyst.r e f e r e n c e s
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